Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart

Inclusion Criteria: * patients with type 2 diabetes for at least one year * treated with oral antidiabetic agents (OADs) for at least 6 months * Baseline C-peptide ≥0.1 nmol/L * BMI (body mass index) between 30 and 40 kg/m2 * HbA1c (glycosylated hemoglobin) \< 8.5% * signed informed consent Exclusion Criteria: * type I diabetes mellitus * current treatment with insulin * pregnant and breast-feeding women * any medication known to influence insulin sensitivity * current treatment with systemic corticosteroids * history of acute metabolic complications in the past 3 months * recurrent severe hypoglycaemia or hypoglycaemic unawareness * active proliferative diabetic retinopathy and known diabetic gastroparesis * impaired hepatic function, as shown but not limited to ALT or AST above 2 times the upper limit of normal * clinically relevant illness such as nephropathy and impaired renal function as shown by clearance \< 30 ml/min * any history or presence of clinically relevant abnormality, medical condition (cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic, ocular or infectious disease; any acute infectious disease or signs of acute illness making implementation of the protocol or interpretation of the results difficult * hypersensitivity to insulins or insulin analogs The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.